NCT05337254View on ClinicalTrials.gov

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions

MigraineMigraine With AuraMigraine Without Aura

Interventions

DRUG

Dihydroergotamine

Dihydroergotamine intranasal powder

DRUG

Dihydroergotamine

Dihydroergotamine intramuscular injection

DRUG

Dihydroergotamine

Dihydroergotamine intranasal spray

Trial Locations (1)

33126

Quotient Sciences Miami Inc., Miami

All Listed Sponsors

lead

Satsuma Pharmaceuticals, Inc.

INDUSTRY

NCT05337254 - A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects | Biotech Hunter | Biotech Hunter